Bartosz Pula1, Bozena Werynska2, Mateusz Olbromski1, Beata Muszczynska-Bernhard3, Mariusz Chabowski4, Dariusz Janczak5, Maciej Zabel6, Marzena Podhorska-Okolow1, Piotr Dziegiel7. 1. Department of Histology and Embryology, Medical University, Wroclaw, Poland. 2. Department of Pulmonology and Pulmonary Tumors, Medical University, Wroclaw, Poland. 3. Laboratory of Histopathology, Lower Silesia Centre of Pulmonary Diseases, Wroclaw, Poland. 4. Surgery Department, 4th Military Teaching Hospital, Wroclaw, Poland. 5. Surgery Department, 4th Military Teaching Hospital, Wroclaw, Poland Department of Clinical Proceedings, Medical University, Wroclaw, Poland. 6. Department of Histology and Embryology, Medical University, Wroclaw, Poland Department of Histology and Embryology, Medical University, Poznan, Poland. 7. Department of Histology and Embryology, Medical University, Wroclaw, Poland Department of Physiotherapy, Wroclaw University School of Physical Education, Wroclaw, Poland piotr.dziegiel@umed.wroc.pl.
Abstract
BACKGROUND: Nogo-B was recently shown to be involved in proliferation, apoptosis and invasiveness of cancer cells, whereas its specific receptor (NgBR) was found to be up-regulated in estrogen receptor-α positive breast cancer. No data are currently available concerning their expression in non-small cell lung carcinomas (NSCLC). MATERIALS AND METHODS: Expression of Nogo isoforms and NgBR was studied in 191 NSCLC. RESULTS: Higher Nogo-A/B immunoreactivity was noted in cancer cells of squamous cell carcinomas (SQC) compared to adenocarcinomas (p<0.001). Stage II-IV tumors had the lowest Nogo-A/B expression (p<0.0001) compared to stage I cases. Nogo-A/B expression decreased with increasing SQC malignancy grade (p=0.026). Significant NgBR mRNA down-regulation was associated with larger primary tumor size (p=0.039), lymph node involvement (p=0.039) and advancement stage (p=0.0054). Low NgBR mRNA expression predicted poor patients outcome (p=0.029). CONCLUSION: The current data may point to the involvement of Nogo isoforms and NgBR in the pathogenesis of NSCLC. Copyright
BACKGROUND:Nogo-B was recently shown to be involved in proliferation, apoptosis and invasiveness of cancer cells, whereas its specific receptor (NgBR) was found to be up-regulated in estrogen receptor-α positive breast cancer. No data are currently available concerning their expression in non-small cell lung carcinomas (NSCLC). MATERIALS AND METHODS: Expression of Nogo isoforms and NgBR was studied in 191 NSCLC. RESULTS: Higher Nogo-A/B immunoreactivity was noted in cancer cells of squamous cell carcinomas (SQC) compared to adenocarcinomas (p<0.001). Stage II-IV tumors had the lowest Nogo-A/B expression (p<0.0001) compared to stage I cases. Nogo-A/B expression decreased with increasing SQC malignancy grade (p=0.026). Significant NgBR mRNA down-regulation was associated with larger primary tumor size (p=0.039), lymph node involvement (p=0.039) and advancement stage (p=0.0054). Low NgBR mRNA expression predicted poor patients outcome (p=0.029). CONCLUSION: The current data may point to the involvement of Nogo isoforms and NgBR in the pathogenesis of NSCLC. Copyright